Hi all,

Y Combinator is getting even more serious about Bio with the launch of YC Bio, a new way to fund early-stage life science companies that are still in the lab phase. Sam Altman spoke at SynBioBeta in 2015 on the growing impact of bio inside of YC. Their first focus will be on longevity companies.

Manus Bio received funding from the Bill & Melinda Gates Foundation to develop a fermentation process for low-cost manufacturing of artemisinin, Christine Santos will be speaking at our October event. Congratulations to DMC Biotechnologies which just raised $1.75M for a new fermentation-based manufacturing platform aiming to reduce biological complexity. Congratulations also to Bell Biosystems on their pre-clinical safety study of their Magnelle-powered Cell Therapies.

Sam Altman, President of Y Combinator.

On the blog this week, we discuss the need for synthetic biology to reach mass commercialization and adoption, and how we can accelerate this process. We also reflect on why scientists should be outspoken on issues like raw water.

The F3 Team is hosting two public webinars on January 25th and 26th to discuss the F3 Fish Oil Challenge. The fish oil alternatives field has attracted interest from big players such as Cargill, Skretting, DuPont, Calysta, and other synthetic biology firms due in part to the technology's multiple uses.

This newsletter is now in its 7th year and is read by over 5500 people. Next week, we’ll be sending our 200th digest! We will also be opening registration for SynBioBeta 2018 with a special priced launch week until January 31st, so stay tuned!

Regards,John

Who's Hiring?

Product Scientist: Opentrons, New YorkSenior Scientist, Strain Engineering: Amyris, Emeryville, CaliforniaSenior Scientist, Enzyme Engineering: Amyris, Emeryville, CaliforniaScientist, Cytochrome P450 Engineering: Amyris, Emeryville, CaliforniaScientist, Strain Performance Optimization, PD&E: Amyris, Emeryville, CaliforniaSenior Director, Separations Process Development: Amyris, Emeryville, CaliforniaFeature your job here, click here to contact us

News

Building Biotech on the Success of Semiconductors: an Interview with CustomArray CEO Brooke Anderson about GenScript's Recent AcquisitionSynthetic biologists have created genetically engineered fruit flies and yeasts that cannot breed with their wild counterparts (Nature)RebelBio launches a new biotech cohort in LondonThe Future of Humans: Gene Editing and the Unthinkable Power to Control Evolution, with Jennifer Doudna, January 18An interview with Jennifer Holmgren, CEO of LanzaTech: “We want to see a Carbon Smart Future take off” (IL Bioeconomista)A Crash Course in the Basics of Finance in Biotechnology (Labiotech)Researchers use AI to improve accuracy of gene editing with CRISPR (Microsoft)Tech Conference Alert: Register for DeveloperWeek 2018 and Save $300CRISPR-edited plants reach market in record timeBacteriophage Therapeutics Company AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common StockInovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy To Evaluate Novel Cancer Immunotherapy CombinationsEstimation of a 69 % reduction in greenhouse gases emissions for fully renewable ETBE compared to fossil gasolineSocial, cultural and ethical aspects of synthetic biology: A scientist’s perspective

Copyright © %%current_year_YYYY%%, All rights reserved.SynBioBeta1547 Palos Verdes Mall, #411Walnut Creek, CA 94597About Us | Update Preferences | Unsubscribe | View email in your browser